Q3 2023 13F Holders as of 9/30/2023
-
Type / Class
-
Equity / Common Stock, $0.0001 par value
-
Shares outstanding
-
5.46M
-
Number of holders
-
16
-
Total 13F shares, excl. options
-
722K
-
Shares change
-
+554K
-
Total reported value, excl. options
-
$438K
-
Value change
-
+$334K
-
Put/Call ratio
-
0.16
-
Number of buys
-
11
-
Number of sells
-
-3
-
Price
-
$0.61
Significant Holders of 180 Life Sciences Corp. - Common Stock, $0.0001 par value (ATNF) as of Q3 2023
20 filings reported holding ATNF - 180 Life Sciences Corp. - Common Stock, $0.0001 par value as of Q3 2023.
180 Life Sciences Corp. - Common Stock, $0.0001 par value (ATNF) has 16 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 722K shares
of 5.46M outstanding shares and own 13.23% of the company stock.
Largest 10 shareholders include CHARLES SCHWAB INVESTMENT MANAGEMENT INC (349K shares), ARMISTICE CAPITAL, LLC (131K shares), RENAISSANCE TECHNOLOGIES LLC (96.1K shares), VANGUARD GROUP INC (47.9K shares), GEODE CAPITAL MANAGEMENT, LLC (30.5K shares), Virtu Financial LLC (15.1K shares), BlackRock Inc. (14.7K shares), CITADEL ADVISORS LLC (14K shares), HRT FINANCIAL LP (10.1K shares), and Tower Research Capital LLC (TRC) (9.63K shares).
This table shows the top 16 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.